We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 5 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , Corcept Therapeutics Inc. (CORT - Free Report) , Precigen, Inc. (PGEN - Free Report) and Bausch Health Companies Inc. (BHC - Free Report) .
Here are highlights from Monday’s Analyst Blog:
4 Low-Beta Healthcare Stocks to Buy Amid Rate Hike Concerns
Wall Street has remained volatile over the past few months. Major indexes have hit record highs multiple times but have given up substantial gains as investors’ sentiment remains low amid ongoing tensions in the Middle East and high inflation.
The Federal Reserve hiked interest rates in its September policy meeting for the first time in three years in its bid to tame inflation. Investors now fear that another rate hike in the Federal Reserve’s next policy meeting could cripple their spending power. These factors could keep markets volatile for a longer period.
Given this situation, it would be ideal to invest in low-beta defensive stocks from the healthcare sector, namely, Abbott Laboratories, Corcept Therapeutics Inc., Precigen, Inc. and Bausch Health Companies Inc.
Fears of Another Rate Hike Grow
The Federal Reserve hiked interest rates by a quarter percentage point in its September FOMC meeting, taking its target range to 3.75% to 4%, as inflation remained elevated. It was the first hike in more than three years. Although inflation eased substantially last year, it remained above the Fed’s 2% target.
However, inflation started climbing in the second quarter as oil prices surged, making goods and services costlier, after war broke out between the United States and Iran in late February.
Tensions escalated further last month after both the United States and Iran resumed attacks following a fragile ceasefire and failed negotiations. Last week, President Donald Trump said a delegation from Iran met with U.S. officials and that the meeting went well and lasted three hours.
However, there are still no signs of negotiations between the two countries. The consumer price index (CPI) jumped 0.4% sequentially in August. The annual CPI rate came in at 3.4%. Core CPI, which strips out volatile food and energy prices, rose 0.3% sequentially in August, taking the annual rate to 2.4%.
The Federal Reserve also hinted at another rate hike by the end of this year. Investors fear that oil prices could surge further if the Middle East tensions continue for a longer period, which could see the Fed hike interest rates at its October FOMC meeting.
The Consumer Confidence index fell 6.7% to 81.9 in September, to hit its lowest level since April 2014, the Conference Board said on Tuesday. A rate hike means higher borrowing costs, which will impact the purchasing power of consumers further.
4 Low-Beta Healthcare Stocks With Upside
Abbott Laboratories
Abbott Laboratories is a diversified healthcare company based in Abbott Park, IL. ABT discovers, develops, manufactures and sells healthcare products globally. Abbott’s products are sold in more than 160 countries. The company has about 122,000 employees.
Abbott Laboratories has an expected earnings growth rate of 7.2% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the past 60 days. ABT has a beta of 0.59 and carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders, which are associated with the activity of the hormone cortisol, also known as the stress hormone.
Corcept Therapeutics has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 64.6% over the past 60 days. ABT has a beta of 0.40 and sports a Zacks Rank #1.
Precigen
Precigen, Inc. is a biopharmaceutical company. It specializes in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. PGEN’s transformative therapeutic platforms, including UltraCAR-T, AdenoVerse cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries.
Precigen has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved more than 100% over the past 60 days. PGEN has a beta of 0.92 and sports a Zacks Rank #1.
Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company focused on developing, manufacturing and marketing products across key therapeutic areas such as gastroenterology, hepatology, neurology and dermatology. BHC portfolio includes branded and generic drugs, branded generics, over-the-counter products and aesthetic medical devices.
Bausch Health Companies has an expected earnings growth rate of 16.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 7.4% over the past 60 days. BHC has a beta of 0.37 and sports a Zacks Rank #1.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
For Immediate Release
Chicago, IL – October 5 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (ABT - Free Report) , Corcept Therapeutics Inc. (CORT - Free Report) , Precigen, Inc. (PGEN - Free Report) and Bausch Health Companies Inc. (BHC - Free Report) .
Here are highlights from Monday’s Analyst Blog:
4 Low-Beta Healthcare Stocks to Buy Amid Rate Hike Concerns
Wall Street has remained volatile over the past few months. Major indexes have hit record highs multiple times but have given up substantial gains as investors’ sentiment remains low amid ongoing tensions in the Middle East and high inflation.
The Federal Reserve hiked interest rates in its September policy meeting for the first time in three years in its bid to tame inflation. Investors now fear that another rate hike in the Federal Reserve’s next policy meeting could cripple their spending power. These factors could keep markets volatile for a longer period.
Given this situation, it would be ideal to invest in low-beta defensive stocks from the healthcare sector, namely, Abbott Laboratories, Corcept Therapeutics Inc., Precigen, Inc. and Bausch Health Companies Inc.
Fears of Another Rate Hike Grow
The Federal Reserve hiked interest rates by a quarter percentage point in its September FOMC meeting, taking its target range to 3.75% to 4%, as inflation remained elevated. It was the first hike in more than three years. Although inflation eased substantially last year, it remained above the Fed’s 2% target.
However, inflation started climbing in the second quarter as oil prices surged, making goods and services costlier, after war broke out between the United States and Iran in late February.
Tensions escalated further last month after both the United States and Iran resumed attacks following a fragile ceasefire and failed negotiations. Last week, President Donald Trump said a delegation from Iran met with U.S. officials and that the meeting went well and lasted three hours.
However, there are still no signs of negotiations between the two countries. The consumer price index (CPI) jumped 0.4% sequentially in August. The annual CPI rate came in at 3.4%. Core CPI, which strips out volatile food and energy prices, rose 0.3% sequentially in August, taking the annual rate to 2.4%.
The Federal Reserve also hinted at another rate hike by the end of this year. Investors fear that oil prices could surge further if the Middle East tensions continue for a longer period, which could see the Fed hike interest rates at its October FOMC meeting.
The Consumer Confidence index fell 6.7% to 81.9 in September, to hit its lowest level since April 2014, the Conference Board said on Tuesday. A rate hike means higher borrowing costs, which will impact the purchasing power of consumers further.
4 Low-Beta Healthcare Stocks With Upside
Abbott Laboratories
Abbott Laboratories is a diversified healthcare company based in Abbott Park, IL. ABT discovers, develops, manufactures and sells healthcare products globally. Abbott’s products are sold in more than 160 countries. The company has about 122,000 employees.
Abbott Laboratories has an expected earnings growth rate of 7.2% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the past 60 days. ABT has a beta of 0.59 and carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders, which are associated with the activity of the hormone cortisol, also known as the stress hormone.
Corcept Therapeutics has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 64.6% over the past 60 days. ABT has a beta of 0.40 and sports a Zacks Rank #1.
Precigen
Precigen, Inc. is a biopharmaceutical company. It specializes in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. PGEN’s transformative therapeutic platforms, including UltraCAR-T, AdenoVerse cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries.
Precigen has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved more than 100% over the past 60 days. PGEN has a beta of 0.92 and sports a Zacks Rank #1.
Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company focused on developing, manufacturing and marketing products across key therapeutic areas such as gastroenterology, hepatology, neurology and dermatology. BHC portfolio includes branded and generic drugs, branded generics, over-the-counter products and aesthetic medical devices.
Bausch Health Companies has an expected earnings growth rate of 16.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 7.4% over the past 60 days. BHC has a beta of 0.37 and sports a Zacks Rank #1.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.